JPMorgan Chase & Co. Acquires 182,314 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

JPMorgan Chase & Co. grew its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 585.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 213,431 shares of the company’s stock after acquiring an additional 182,314 shares during the period. JPMorgan Chase & Co. owned about 0.53% of Keros Therapeutics worth $3,379,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Barclays PLC increased its holdings in Keros Therapeutics by 140.1% in the 3rd quarter. Barclays PLC now owns 60,014 shares of the company’s stock worth $3,484,000 after acquiring an additional 35,022 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Keros Therapeutics by 6.8% during the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock valued at $42,146,000 after purchasing an additional 46,041 shares during the period. SG Americas Securities LLC purchased a new position in shares of Keros Therapeutics during the 4th quarter valued at $388,000. Exchange Traded Concepts LLC bought a new position in Keros Therapeutics in the 4th quarter worth $99,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in Keros Therapeutics by 19.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company’s stock worth $136,000 after buying an additional 1,372 shares in the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the acquisition, the insider now owns 4,392,737 shares of the company’s stock, valued at approximately $44,498,425.81. This trade represents a 27.01 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 22.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on KROS shares. Cantor Fitzgerald lowered Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 21st. Scotiabank reduced their price objective on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a research report on Thursday, January 16th. Truist Financial dropped their target price on shares of Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday, April 9th. Oppenheimer decreased their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating on the stock in a research note on Thursday, January 16th. Finally, Piper Sandler reduced their target price on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a report on Friday, January 17th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $40.33.

Keros Therapeutics Trading Up 1.6 %

KROS stock opened at $14.30 on Tuesday. Keros Therapeutics, Inc. has a 12 month low of $9.12 and a 12 month high of $72.37. The stock has a market cap of $580.04 million, a PE ratio of -2.74 and a beta of 1.39. The company has a 50-day moving average price of $11.25 and a 200 day moving average price of $28.70.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $3.04 million for the quarter, compared to analysts’ expectations of $37.32 million. Sell-side analysts forecast that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.